Key Points
- PTC VP Mark Elliott Boulding sold 2,265 shares on April 6 at an average price of $69.45 for $157,304.25, a trade executed under a pre-arranged Rule 10b5-1 plan that reduced his stake by 2.11% to 105,212 shares (≈$7.31M).
- He had previously sold 15,260 shares across January and February in multiple tranches, indicating a continuing pattern of insider disposals.
- PTC recently reported a major earnings miss, posting ($1.67) EPS vs. a ($0.21) consensus and a 22.7% year-over-year revenue decline, though analysts’ consensus remains a "Moderate Buy" with a $82.71 price target.
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) VP Mark Elliott Boulding sold 2,265 shares of the stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $69.45, for a total transaction of $157,304.25. Following the completion of the transaction, the vice president directly owned 105,212 shares of the company's stock, valued at approximately $7,306,973.40. The trade was a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mark Elliott Boulding also recently made the following trade(s):
- On Thursday, February 19th, Mark Elliott Boulding sold 3,019 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.48, for a total transaction of $209,760.12.
- On Wednesday, February 18th, Mark Elliott Boulding sold 3,081 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.36, for a total transaction of $213,698.16.
- On Tuesday, February 17th, Mark Elliott Boulding sold 2,813 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.29, for a total transaction of $194,912.77.
- On Friday, January 9th, Mark Elliott Boulding sold 2,314 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.93, for a total transaction of $180,330.02.
- On Thursday, January 8th, Mark Elliott Boulding sold 4,033 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.56, for a total transaction of $308,766.48.
PTC Therapeutics Price Performance
PTCT stock opened at $71.26 on Thursday. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $87.50. The company has a market cap of $5.90 billion, a P/E ratio of 9.21 and a beta of 0.55. The firm has a 50-day moving average of $68.71 and a 200 day moving average of $71.24.
PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($1.46). PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The company had revenue of $164.68 million during the quarter, compared to the consensus estimate of $281.45 million. During the same period in the previous year, the company earned ($0.85) earnings per share. PTC Therapeutics's quarterly revenue was down 22.7% on a year-over-year basis. On average, equities research analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.
Institutional Investors Weigh In On PTC Therapeutics
A number of institutional investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its holdings in shares of PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 236 shares during the last quarter. Allworth Financial LP grew its holdings in shares of PTC Therapeutics by 63.8% during the fourth quarter. Allworth Financial LP now owns 634 shares of the biopharmaceutical company's stock valued at $48,000 after buying an additional 247 shares during the last quarter. Optiver Holding B.V. grew its holdings in shares of PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 249 shares during the last quarter. Measured Wealth Private Client Group LLC grew its holdings in shares of PTC Therapeutics by 5.6% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 4,963 shares of the biopharmaceutical company's stock valued at $377,000 after buying an additional 265 shares during the last quarter. Finally, IFP Advisors Inc grew its holdings in shares of PTC Therapeutics by 68.1% during the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company's stock valued at $47,000 after buying an additional 310 shares during the last quarter.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on PTCT shares. Jefferies Financial Group cut shares of PTC Therapeutics from a "buy" rating to a "hold" rating and cut their price objective for the stock from $91.00 to $76.00 in a report on Monday, March 30th. Weiss Ratings restated a "hold (c)" rating on shares of PTC Therapeutics in a report on Monday, December 29th. TD Cowen restated a "hold" rating on shares of PTC Therapeutics in a report on Thursday, January 29th. Bank of America cut their price objective on shares of PTC Therapeutics from $97.00 to $93.00 and set a "buy" rating on the stock in a report on Friday, February 20th. Finally, Royal Bank Of Canada cut their price objective on shares of PTC Therapeutics from $87.00 to $82.00 and set a "sector perform" rating on the stock in a report on Friday, February 20th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $82.71.
View Our Latest Stock Report on PTCT
About PTC Therapeutics
(
Get Free Report)
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.
Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
